Vivian P. Bykerk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vivian P. Bykerk has a total of 457 co-authors. Here are the top co-authors by number of shared publications:
- Janet Elizabeth Pope
University of Western Ontario, London, Ontario, Canada
17 shared publications - Glen Stewart Hazlewood
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, University of British Columbia, Vancouver, Canada; McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, Canada
15 shared publications - Susan J. Bartlett
Department of Medicine, McGill University, Montreal, Quebec, Canada
14 shared publications - J. Carter Thorne
J.C. Thorne, MD, FRCPC, Assistant Past Professor, Department of Medicine, University of Toronto; Medical Director, The Arthritis Program; Board Chair Centre of Arthritis Excellence, Newmarket, Ontario, Canada
13 shared publications - Carol A. Hitchon
Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada
10 shared publications - Orit Schieir
O. Schieir, PhD, McGill University, Department of Medicine, Montreal, QC, Canada
10 shared publications
Latest Publications
- 28 August 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (11) , 2129-2135
Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year
- 28 August 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (11) , 2129-2135
Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year
- 15 January 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (9) , 971-976
Stressful Life Events in the Year Prior to Diagnosis and Associations With Rheumatoid Arthritis Characteristics at Presentation and 1 Year Later
Objective: To evaluate the relationship between major life stressors in the year prior to diagnosis and rheumatoid arthritis (RA) symptoms and function at diagnosis and at 1 year. Methods: Data were from adults with RA in the Canadian Early Arthritis Cohort, a multicenter inception cohort from January 2007 to March 2017 with ≥ 12 months of follow-up. Patients completed questionnaires about stressful life events in the prior year: Health Assessment Questionnaire–Disability Index (HAQ-DI); 12-item Short Form Health Survey; and 11-point rating scales of sleep, fatigue, pain, and patient global assessment (PtGA). Group characteristics were compared with ANOVA or chi-square test, and adjusted multivariable regression models examined the effect of stressors on symptoms and function at 1 year. Results: The 1933 participants were mostly White (87%) women (72%) with a mean age of 55 years; 52% reported ≥ 1 stressors in the year prior to diagnosis. Around diagnosis, patients reporting major stressors had significantly worse mean HAQ-DI, depression, sleep, fatigue, pain, and PtGA, which generally worsened with the type and number of stressors. At 1 year, the odds of depression and disability, and ratings of pain, fatigue, poor sleep, and PtGA generally increased with an increasing number of stressors, though Simplified Disease Activity Index (SDAI) improved similarly among groups. Conclusion: Fifty-two percent of patients with newly diagnosed RA reported stressful life events in the year prior to diagnosis that were associated with worse disability, depression, pain, fatigue, sleep, and well-being, but not SDAI, at diagnosis. Poorer patient-reported outcomes persisted at 1 year despite similar improvements in SDAI. Results highlight the potential independent contributions of environmental and psychological factors in the onset and course of RA.
- 15 January 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (9) , 971-976
Stressful Life Events in the Year Prior to Diagnosis and Associations With Rheumatoid Arthritis Characteristics at Presentation and 1 Year Later
Objective: To evaluate the relationship between major life stressors in the year prior to diagnosis and rheumatoid arthritis (RA) symptoms and function at diagnosis and at 1 year. Methods: Data were from adults with RA in the Canadian Early Arthritis Cohort, a multicenter inception cohort from January 2007 to March 2017 with ≥ 12 months of follow-up. Patients completed questionnaires about stressful life events in the prior year: Health Assessment Questionnaire–Disability Index (HAQ-DI); 12-item Short Form Health Survey; and 11-point rating scales of sleep, fatigue, pain, and patient global assessment (PtGA). Group characteristics were compared with ANOVA or chi-square test, and adjusted multivariable regression models examined the effect of stressors on symptoms and function at 1 year. Results: The 1933 participants were mostly White (87%) women (72%) with a mean age of 55 years; 52% reported ≥ 1 stressors in the year prior to diagnosis. Around diagnosis, patients reporting major stressors had significantly worse mean HAQ-DI, depression, sleep, fatigue, pain, and PtGA, which generally worsened with the type and number of stressors. At 1 year, the odds of depression and disability, and ratings of pain, fatigue, poor sleep, and PtGA generally increased with an increasing number of stressors, though Simplified Disease Activity Index (SDAI) improved similarly among groups. Conclusion: Fifty-two percent of patients with newly diagnosed RA reported stressful life events in the year prior to diagnosis that were associated with worse disability, depression, pain, fatigue, sleep, and well-being, but not SDAI, at diagnosis. Poorer patient-reported outcomes persisted at 1 year despite similar improvements in SDAI. Results highlight the potential independent contributions of environmental and psychological factors in the onset and course of RA.
- Open Access
- 13 September 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (4) , rkaf120
Predictors of depression trajectories during the COVID-19 pandemic in adults with rheumatoid arthritis: results from the Canadian Early Arthritis Cohort
Objectives: Growing evidence points to mental health impacts of coronavirus disease 2019 (COVID-19). We explored trajectories of depressive symptoms in the year pre- and 2 years post-pandemic onset in adults with RA. Methods: Data are from the Canadian Early Arthritis Cohort (CATCH), a prospective, multicentre, early RA cohort of Canadian adults treated by rheumatologists. Pre-pandemic, participants completed patient-reported outcome measures and rheumatology exams in person. After March 2020, patient-reported outcomes were collected at in-person and virtual visits. We used group-based trajectory modelling to explore longitudinal patterns of depressive symptoms prior to and throughout the COVID-19 pandemic and multinomial regression to identify factors associated with depression trajectory group. Results: A total of 989 participants had a mean age of 60 years (s.d. 14), RA for 6 years (s.d. 4) and were mostly white (84%) and female (73%) with some college education (60%). Most (77%) were in Clinical Disease Activity Index remission/low disease activity prior to the pandemic. We identified four trajectories: resilient (no symptoms throughout: 60%), worsening (none–mild: 22%), improving (mild–minimal: 8%) and persistent (moderate–severe throughout: 9%). Age, sex, race, education, pain, physical and social functioning, fibromyalgia and history of anxiety/depression were associated with different trajectories. Conclusion: Although 60% had a consistent affect during the first 2 years of the pandemic, mood worsened in greater than one in five, suggesting a cumulative impact over time. Biological, psychological and social factors and worse pre-pandemic symptoms and function were associated with a greater risk of depression during the pandemic. Identifying at-risk groups impacted by major stressors like the pandemic may offer new opportunities to personalize treatment, allocate resources, reduce disease flares and improve outcomes.
- 13 September 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (4) , rkaf120
Open AccessPredictors of depression trajectories during the COVID-19 pandemic in adults with rheumatoid arthritis: results from the Canadian Early Arthritis Cohort
Objectives: Growing evidence points to mental health impacts of coronavirus disease 2019 (COVID-19). We explored trajectories of depressive symptoms in the year pre- and 2 years post-pandemic onset in adults with RA. Methods: Data are from the Canadian Early Arthritis Cohort (CATCH), a prospective, multicentre, early RA cohort of Canadian adults treated by rheumatologists. Pre-pandemic, participants completed patient-reported outcome measures and rheumatology exams in person. After March 2020, patient-reported outcomes were collected at in-person and virtual visits. We used group-based trajectory modelling to explore longitudinal patterns of depressive symptoms prior to and throughout the COVID-19 pandemic and multinomial regression to identify factors associated with depression trajectory group. Results: A total of 989 participants had a mean age of 60 years (s.d. 14), RA for 6 years (s.d. 4) and were mostly white (84%) and female (73%) with some college education (60%). Most (77%) were in Clinical Disease Activity Index remission/low disease activity prior to the pandemic. We identified four trajectories: resilient (no symptoms throughout: 60%), worsening (none–mild: 22%), improving (mild–minimal: 8%) and persistent (moderate–severe throughout: 9%). Age, sex, race, education, pain, physical and social functioning, fibromyalgia and history of anxiety/depression were associated with different trajectories. Conclusion: Although 60% had a consistent affect during the first 2 years of the pandemic, mood worsened in greater than one in five, suggesting a cumulative impact over time. Biological, psychological and social factors and worse pre-pandemic symptoms and function were associated with a greater risk of depression during the pandemic. Identifying at-risk groups impacted by major stressors like the pandemic may offer new opportunities to personalize treatment, allocate resources, reduce disease flares and improve outcomes.
- Top Cited PapersOpen Access
- 17 March 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (6)
Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disease currently with no universally highly effective prevention strategies. Identifying pathogenic immune phenotypes in at-risk populations prior to clinical onset is crucial to establishing effective prevention strategies. Here, we applied multimodal single-cell technologies (mass cytometry and CITE-Seq) to characterize the immunophenotypes in blood from at-risk individuals (ARIs) identified through the presence of serum antibodies against citrullinated protein antigens (ACPAs) and/or first-degree relative (FDR) status, as compared with patients with established RA and people in a healthy control group. We identified significant cell expansions in ARIs compared with controls, including CCR2 + CD4 + T cells, T peripheral helper (Tph) cells, type 1 T helper cells, and CXCR5 + CD8 + T cells. We also found that CD15 + classical monocytes were specifically expanded in ACPA-negative FDRs, and an activated PAX5 lo naive B cell population was expanded in ACPA-positive FDRs. Further, we uncovered the molecular phenotype of the CCR2 + CD4 + T cells, expressing high levels of Th17- and Th22-related signature transcripts including CCR6 , IL23R , KLRB1 , CD96 , and IL22 . Our integrated study provides a promising approach to identify targets to improve prevention strategy development for RA.
- 17 March 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (6)
Top Cited PapersOpen AccessDeep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disease currently with no universally highly effective prevention strategies. Identifying pathogenic immune phenotypes in at-risk populations prior to clinical onset is crucial to establishing effective prevention strategies. Here, we applied multimodal single-cell technologies (mass cytometry and CITE-Seq) to characterize the immunophenotypes in blood from at-risk individuals (ARIs) identified through the presence of serum antibodies against citrullinated protein antigens (ACPAs) and/or first-degree relative (FDR) status, as compared with patients with established RA and people in a healthy control group. We identified significant cell expansions in ARIs compared with controls, including CCR2 + CD4 + T cells, T peripheral helper (Tph) cells, type 1 T helper cells, and CXCR5 + CD8 + T cells. We also found that CD15 + classical monocytes were specifically expanded in ACPA-negative FDRs, and an activated PAX5 lo naive B cell population was expanded in ACPA-positive FDRs. Further, we uncovered the molecular phenotype of the CCR2 + CD4 + T cells, expressing high levels of Th17- and Th22-related signature transcripts including CCR6 , IL23R , KLRB1 , CD96 , and IL22 . Our integrated study provides a promising approach to identify targets to improve prevention strategy development for RA.
- Open Access
- 15 January 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (5) , 426-435
Association Between Abatacept Exposure Levels and Infection Occurrence in Patients With Rheumatoid Arthritis: Post Hoc Analysis of the AVERT-2 Study
Objective: To determine whether higher serum exposure during subcutaneous (SC) abatacept (ABA) treatment was associated with an increased infection risk in adult patients with early rheumatoid arthritis (RA). Methods: Data from Assessing Very Early Rheumatoid Arthritis Treatment-2 (AVERT2; ClinicalTrials.gov : NCT02504268 ), a randomized, placebo-controlled study in anticitrullinated protein antibody–positive patients with early RA, were analyzed. A post hoc population pharmacokinetic (PPK) analysis was performed. The association between steady-state ABA concentration exposures (ie, steady-state time-averaged serum concentration, steady-state trough serum concentration, steady-state maximum serum concentration) and first infection was evaluated using Kaplan-Meier plots of probability vs time receiving treatment and Cox proportional hazards models. Results: The PK model of SC ABA was defined as a linear 2-compartment model with first-order absorption and elimination, and higher body weight was the only covariate with a clinically relevant effect in the final PPK model. Infections occurred in 330/693 patients treated with ABA + methotrexate (MTX; 47.6%; 11/693 [1.6%] with serious infections) and 134/301 of those treated with ABA placebo + MTX (44.5%; 4/301 [1.3%] with serious infections). Exposure-response analysis demonstrated no exposure relationship for an increased risk of first infection for patients with concomitant use of MTX and glucocorticoids (GCs) during the induction period, baseline GC use, or higher-than-median body weight (> 70 kg) at baseline. Conclusion: This exposure-response analysis of AVERT-2 showed no increase in the risk of first infection, regardless of ABA exposure level, in patients with RA treated with SC ABA. Similarly, no effect on the risk of first infection was found for concomitant MTX and GC use in patients with RA treated with SC ABA + MTX.
- 15 January 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (5) , 426-435
Open AccessAssociation Between Abatacept Exposure Levels and Infection Occurrence in Patients With Rheumatoid Arthritis: Post Hoc Analysis of the AVERT-2 Study
Objective: To determine whether higher serum exposure during subcutaneous (SC) abatacept (ABA) treatment was associated with an increased infection risk in adult patients with early rheumatoid arthritis (RA). Methods: Data from Assessing Very Early Rheumatoid Arthritis Treatment-2 (AVERT2; ClinicalTrials.gov : NCT02504268 ), a randomized, placebo-controlled study in anticitrullinated protein antibody–positive patients with early RA, were analyzed. A post hoc population pharmacokinetic (PPK) analysis was performed. The association between steady-state ABA concentration exposures (ie, steady-state time-averaged serum concentration, steady-state trough serum concentration, steady-state maximum serum concentration) and first infection was evaluated using Kaplan-Meier plots of probability vs time receiving treatment and Cox proportional hazards models. Results: The PK model of SC ABA was defined as a linear 2-compartment model with first-order absorption and elimination, and higher body weight was the only covariate with a clinically relevant effect in the final PPK model. Infections occurred in 330/693 patients treated with ABA + methotrexate (MTX; 47.6%; 11/693 [1.6%] with serious infections) and 134/301 of those treated with ABA placebo + MTX (44.5%; 4/301 [1.3%] with serious infections). Exposure-response analysis demonstrated no exposure relationship for an increased risk of first infection for patients with concomitant use of MTX and glucocorticoids (GCs) during the induction period, baseline GC use, or higher-than-median body weight (> 70 kg) at baseline. Conclusion: This exposure-response analysis of AVERT-2 showed no increase in the risk of first infection, regardless of ABA exposure level, in patients with RA treated with SC ABA. Similarly, no effect on the risk of first infection was found for concomitant MTX and GC use in patients with RA treated with SC ABA + MTX.
- Open Access
- 15 July 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (9) , 940-941
Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #2
We have updated the Canadian Rheumatology Association (CRA) guidelines for rheumatoid arthritis (RA) with 3 recommendations for the use of glucocorticoids (GCs). The recommendations address the use of short-term GCs for RA flares or as bridging therapy when disease-modifying antirheumatic drugs (DMARDs) are initiated or changed, and the use of longterm GCs as adjuncts to DMARDs.
- 15 July 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (9) , 940-941
Open AccessCanadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #2
We have updated the Canadian Rheumatology Association (CRA) guidelines for rheumatoid arthritis (RA) with 3 recommendations for the use of glucocorticoids (GCs). The recommendations address the use of short-term GCs for RA flares or as bridging therapy when disease-modifying antirheumatic drugs (DMARDs) are initiated or changed, and the use of longterm GCs as adjuncts to DMARDs.
- Open Access
- 22 May 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1093348
Clinical implications of synovial tissue phenotypes in rheumatoid arthritis
Autoimmune forms of inflammatory arthritis, such as Rheumatoid Arthritis (RA), are clinically heterogeneous in presentation and disease course. Treatment-related outcomes vary despite patient exposure to similar treatment strategies. It is likely that variation seen in synovial pathogenesis influences outcomes and is heterogeneous outcomes influenced by patient factors, including environmental exposures, microbiota, behaviors, timely access to therapy, and synovial cell variation. Patients’ unique complex factors manifest as specific synovial phenotypes characterized by clusters of synovial cell types and states. Precision medicine aims to use such clinical and biological data to identify the right treatment for the right patient at the right time, enabling patients to achieve sustained remission. Identifying synovial targets susceptible to a given treatment, enabling the choice of effective therapy for a given patient, will realize the goals of precision medicine. Over the last 7 years, improved acquisition and processing of synovial tissue obtained by ultra-sound guided biopsy has enabled researchers to define synovial pathotypes using histologic features and predominant cell types associated with clinical manifestations. Technical advances have enabled single-cell simultaneous sequencing of proteins and gene expression that, through increasingly sophisticated bioinformatics methods, have taken transcriptional and proteomic data to identify diverse and novel cell types and states that cluster in the RA synovium to further define patient subgroups. Synovial pathotypes and endotypes are now integrated into clinical studies and trials to explain clinical heterogeneity in disease course and treatment response. Rapidly evolving clinical-translational research has linked an expanded understanding of RA synovial pathogenesis with clinically meaningful subgroups and treatment outcomes and the clinical heterogeneity in RA.
- 22 May 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1093348
Open AccessClinical implications of synovial tissue phenotypes in rheumatoid arthritis
Autoimmune forms of inflammatory arthritis, such as Rheumatoid Arthritis (RA), are clinically heterogeneous in presentation and disease course. Treatment-related outcomes vary despite patient exposure to similar treatment strategies. It is likely that variation seen in synovial pathogenesis influences outcomes and is heterogeneous outcomes influenced by patient factors, including environmental exposures, microbiota, behaviors, timely access to therapy, and synovial cell variation. Patients’ unique complex factors manifest as specific synovial phenotypes characterized by clusters of synovial cell types and states. Precision medicine aims to use such clinical and biological data to identify the right treatment for the right patient at the right time, enabling patients to achieve sustained remission. Identifying synovial targets susceptible to a given treatment, enabling the choice of effective therapy for a given patient, will realize the goals of precision medicine. Over the last 7 years, improved acquisition and processing of synovial tissue obtained by ultra-sound guided biopsy has enabled researchers to define synovial pathotypes using histologic features and predominant cell types associated with clinical manifestations. Technical advances have enabled single-cell simultaneous sequencing of proteins and gene expression that, through increasingly sophisticated bioinformatics methods, have taken transcriptional and proteomic data to identify diverse and novel cell types and states that cluster in the RA synovium to further define patient subgroups. Synovial pathotypes and endotypes are now integrated into clinical studies and trials to explain clinical heterogeneity in disease course and treatment response. Rapidly evolving clinical-translational research has linked an expanded understanding of RA synovial pathogenesis with clinically meaningful subgroups and treatment outcomes and the clinical heterogeneity in RA.
- 1 February 2024
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 20 (1) , 46-56
The Gap in Knowledge about Tapering Targeted Therapy being used as Monotherapy in Rheumatoid Arthritis: A Systematic Review
Background: Up to 30% of patients with RA are being treated with biologic (b)-disease modifying anti-rheumatic drugs (DMARDs) as monotherapy. Monotherapy with Interleukin (IL)-6 inhibitors(i) and Janus-kinase (JAK)-i has been shown to be effective. Whether patients can taper targeted therapy (bDMARDs and JAK-i) used as monotherapy (targeted monotherapy) is unknown. Objective: To determine the feasibility of tapering of targeted monotherapy in patients with controlled RA. Methods: We conducted a literature search in Medline, Embase and Cochrane Library for prospective studies reporting remission outcomes after tapering targeted monotherapy in RA patients, from 1/2014 - 8 /2021. Results: 5 randomized studies which met our inclusion criteria, evaluating tapering of monotherapy with tumor necrosis factor-inhibitors, tocilizumab, abatacept and baricitinib in RA. Studies were heterogeneous. Three trials studied early RA. Three studies gradually tapered therapy, including 1 dose reduction study. Three studies tapered both biological and conventional-synthetic (cs)-DMARDs. No study compared stopping targeted monotherapy to continuing it. Remission rates were low 14-28% across all studies that stopped targeted monotherapy. The highest remission rate of 72% was reported by the dose reduction study. Trials that studied early RA reported remission rates after tapering ranging 27-72%. Trials tapering therapy in established RA reported rates of remission from 14-20%. Conclusion: There is a crucial gap in published literature to inform on tapering targeted monotherapy in patients with RA. Stopping targeted monotherapy is unlikely to maintain disease control in RA. Dose reduction strategies and early treatment of disease may be associated with more successful tapering, and warrant future study.
- 1 February 2024
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 20 (1) , 46-56
The Gap in Knowledge about Tapering Targeted Therapy being used as Monotherapy in Rheumatoid Arthritis: A Systematic Review
Background: Up to 30% of patients with RA are being treated with biologic (b)-disease modifying anti-rheumatic drugs (DMARDs) as monotherapy. Monotherapy with Interleukin (IL)-6 inhibitors(i) and Janus-kinase (JAK)-i has been shown to be effective. Whether patients can taper targeted therapy (bDMARDs and JAK-i) used as monotherapy (targeted monotherapy) is unknown. Objective: To determine the feasibility of tapering of targeted monotherapy in patients with controlled RA. Methods: We conducted a literature search in Medline, Embase and Cochrane Library for prospective studies reporting remission outcomes after tapering targeted monotherapy in RA patients, from 1/2014 - 8 /2021. Results: 5 randomized studies which met our inclusion criteria, evaluating tapering of monotherapy with tumor necrosis factor-inhibitors, tocilizumab, abatacept and baricitinib in RA. Studies were heterogeneous. Three trials studied early RA. Three studies gradually tapered therapy, including 1 dose reduction study. Three studies tapered both biological and conventional-synthetic (cs)-DMARDs. No study compared stopping targeted monotherapy to continuing it. Remission rates were low 14-28% across all studies that stopped targeted monotherapy. The highest remission rate of 72% was reported by the dose reduction study. Trials that studied early RA reported remission rates after tapering ranging 27-72%. Trials tapering therapy in established RA reported rates of remission from 14-20%. Conclusion: There is a crucial gap in published literature to inform on tapering targeted monotherapy in patients with RA. Stopping targeted monotherapy is unlikely to maintain disease control in RA. Dose reduction strategies and early treatment of disease may be associated with more successful tapering, and warrant future study.
- 1 August 2023
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (9) , 1198-1199
Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #1
We have updated the Canadian Rheumatology Association (CRA) guidelines for rheumatoid arthritis, with a series of best practice statements and a recommendation for the choice of disease-modifying antirheumatic drug therapy after an inadequate response to tumor necrosis factor inhibitors (TNFi). These add to our prior recommendation for tapering of advanced therapy.1
- 1 August 2023
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (9) , 1198-1199
Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #1
We have updated the Canadian Rheumatology Association (CRA) guidelines for rheumatoid arthritis, with a series of best practice statements and a recommendation for the choice of disease-modifying antirheumatic drug therapy after an inadequate response to tumor necrosis factor inhibitors (TNFi). These add to our prior recommendation for tapering of advanced therapy.1
- Open Access
Anticitrullinated peptide antibody epitope expansion and the HLA DRB1 ‘shared epitope’ are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis
Background Immune checkpoint inhibitors (ICI) can potentially cause ICI-inflammatory arthritis (ICI-IA), which often resembles rheumatoid arthritis (RA). In this study, we examined the degree of anticitrullinated peptide antibodies (ACPA) epitope expansion in CCP+ICI-IA and patients with RA. Methods We used clinical data and serum from ICI-IA and patients with RA with early disease as well as longstanding disease. A custom, bead-based antigen array was used to identify IgG ACPA reactivities to 18 putative RA-associated citrullinated proteins. Hierarchical clustering software was used to create a heatmap to identify ACPA levels. Additionally, HLA DRB1 typing was performed on ICI-IA patients as well as controls of patients treated with ICI that did not develop ICI-IA (ICI controls). Results Compared to patients with CCP+RA, patients with CCP+ICI-IA were older (pConclusion Patients with ICI-IA had lower ACPA titres and targeted fewer ACPA epitopes than longstanding patients with RA, and there were no significant differences in the presence of the shared epitope between those that developed ICI-IA and ICI controls. It remains to be determined if ICI-IA represents an accelerated model of RA pathogenesis with ICI triggering a transition from preclinical to clinical disease.
Open AccessAnticitrullinated peptide antibody epitope expansion and the HLA DRB1 ‘shared epitope’ are less common in seropositive checkpoint inhibitor-induced inflammatory arthritis than in longstanding rheumatoid arthritis
Background Immune checkpoint inhibitors (ICI) can potentially cause ICI-inflammatory arthritis (ICI-IA), which often resembles rheumatoid arthritis (RA). In this study, we examined the degree of anticitrullinated peptide antibodies (ACPA) epitope expansion in CCP+ICI-IA and patients with RA. Methods We used clinical data and serum from ICI-IA and patients with RA with early disease as well as longstanding disease. A custom, bead-based antigen array was used to identify IgG ACPA reactivities to 18 putative RA-associated citrullinated proteins. Hierarchical clustering software was used to create a heatmap to identify ACPA levels. Additionally, HLA DRB1 typing was performed on ICI-IA patients as well as controls of patients treated with ICI that did not develop ICI-IA (ICI controls). Results Compared to patients with CCP+RA, patients with CCP+ICI-IA were older (pConclusion Patients with ICI-IA had lower ACPA titres and targeted fewer ACPA epitopes than longstanding patients with RA, and there were no significant differences in the presence of the shared epitope between those that developed ICI-IA and ICI controls. It remains to be determined if ICI-IA represents an accelerated model of RA pathogenesis with ICI triggering a transition from preclinical to clinical disease.